Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$38.07 -4.8%	$47.19	$17.86 ▼ $58.40	$3.06B	-0.18	829,175 shs	511,208 shs
CTNM Contineum Therapeutics	$5.91 -3.7%	$7.83	$5.70 ▼ $22.00	$152.77M	N/A	84,664 shs	29,345 shs
EWTX Edgewise Therapeutics	$12.17 -10.4%	$25.54	$12.02 ▼ $38.12	$1.17B	0.22	1.07 million shs	1.84 million shs
RCKT Rocket Pharmaceuticals	$5.23 -6.0%	$9.27	$5.12 ▼ $26.98	$559.81M	1	1.13 million shs	2.18 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	-4.67%	-8.24%	-10.20%	+41.61%	+72.52%
CTNM Contineum Therapeutics	-9.59%	-17.72%	-1.92%	-57.78%	+612,999,900.00%
EWTX Edgewise Therapeutics	-12.50%	-42.06%	-44.57%	-51.01%	-26.59%
RCKT Rocket Pharmaceuticals	-11.75%	-29.44%	-35.80%	-55.73%	-78.14%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	4.1149 of 5 stars	4.5	1.0	4.7	2.7	1.7	0.0
CTNM Contineum Therapeutics	1.4385 of 5 stars	3.6	1.0	0.0	0.6	0.0	0.6
EWTX Edgewise Therapeutics	1.8042 of 5 stars	3.4	1.0	0.0	2.9	2.5	0.0
RCKT Rocket Pharmaceuticals	4.5547 of 5 stars	4.5	1.0	4.7	1.3	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$76.29	100.40% Upside
CTNM Contineum Therapeutics	3.17	Buy	$24.80	319.98% Upside
EWTX Edgewise Therapeutics	2.75	Moderate Buy	$40.38	231.84% Upside
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$43.00	722.97% Upside

Current Analyst Ratings Breakdown

Latest CTNM, EWTX, RCKT, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00
4/2/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$50.00 ➝ $14.00
3/13/2025	CTNM Contineum Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
3/12/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/7/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$25.00 ➝ $25.00
3/7/2025	CTNM Contineum Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $16.00
3/7/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$50.00
3/4/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $56.00
3/3/2025	AKRO Akero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $75.00
3/3/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $15.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$9.61 per share	N/A
CTNM Contineum Therapeutics	$50M	3.06	$0.93 per share	6.35	($3.72) per share	-1.59
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$151.76M	-$3.75	N/A	N/A	N/A	N/A	-32.46%	-29.83%	5/9/2025 (Estimated)
CTNM Contineum Therapeutics	$22.72M	-$4.90	N/A	N/A	N/A	N/A	-49.92%	-20.52%	5/15/2025 (Estimated)
EWTX Edgewise Therapeutics	-$100.16M	-$1.45	N/A	N/A	N/A	N/A	-26.83%	-25.67%	5/8/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.73	N/A	N/A	N/A	N/A	-62.62%	-54.17%	5/5/2025 (Estimated)

Latest CTNM, EWTX, RCKT, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A
2/28/2025	Q4 2024	AKRO Akero Therapeutics	-$0.98	-$0.99	-$0.01	-$0.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.05	17.25	17.25
CTNM Contineum Therapeutics	N/A	37.06	37.06
EWTX Edgewise Therapeutics	N/A	26.35	26.35
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
CTNM Contineum Therapeutics	N/A
EWTX Edgewise Therapeutics	N/A
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.94%
CTNM Contineum Therapeutics	N/A
EWTX Edgewise Therapeutics	24.11%
RCKT Rocket Pharmaceuticals	28.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.62 million	64.26 million	Optionable
CTNM Contineum Therapeutics	31	25.87 million	N/A	N/A
EWTX Edgewise Therapeutics	60	95.21 million	71.86 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.63 million	65.18 million	Optionable

CTNM, EWTX, RCKT, and AKRO Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 4.5% Higher - Here's What Happened

April 4 at 11:44 AM | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Wellington Management Group LLP

April 4 at 4:34 AM | marketbeat.com

Pictet Asset Management Holding SA Sells 68,736 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

April 3 at 4:18 AM | marketbeat.com

Rocket buys largest mortgage servicer

April 2 at 5:48 PM | abccolumbia.com

Why Rocket Pharmaceuticals, Inc.’s (RCKT) Stock Is Down 12.89%

April 2 at 5:48 PM | aaii.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week Low - Here's Why

April 2 at 4:11 AM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 15.6% - What's Next?

April 1 at 2:00 PM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week Low - What's Next?

March 27, 2025 | marketbeat.com

EFG Asset Management North America Corp. Has $1.83 Million Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

March 27, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 6.1% - Should You Sell?

March 26, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

March 24, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Boosted by Privium Fund Management B.V.

March 20, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Down - What's Next?

March 19, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 4.5% - Here's What Happened

March 18, 2025 | marketbeat.com

one8zero8 LLC Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

March 17, 2025 | marketbeat.com

Rocket Lab Leaders Sued by Shareholder Over Launch Delay Report

March 15, 2025 | news.bloomberglaw.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Moderate Buy" from Brokerages

March 14, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up - Should You Buy?

March 13, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Coverage Initiated by Analysts at BMO Capital Markets

March 13, 2025 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week Low - Here's What Happened

March 12, 2025 | marketbeat.com

Rocket Pharmaceuticals initiated with an Outperform at BMO Capital

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, EWTX, RCKT, and AKRO Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$38.07 -1.92 (-4.81%)

As of 12:47 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Contineum Therapeutics NASDAQ:CTNM

$5.90 -0.23 (-3.67%)

As of 12:46 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Edgewise Therapeutics NASDAQ:EWTX

$12.17 -1.41 (-10.41%)

As of 12:47 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Rocket Pharmaceuticals NASDAQ:RCKT

$5.22 -0.34 (-6.03%)

As of 12:47 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time